Baxter International Inc (NYSE:BAX) SVP Jeanne K. Mason sold 33,350 shares of Baxter International stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the sale, the senior vice president now owns 124,609 shares in the company, valued at approximately $8,130,737.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Baxter International Inc (BAX) opened at $64.05 on Friday. The firm has a market cap of $34,607.72, a PE ratio of 26.25, a P/E/G ratio of 2.12 and a beta of 0.69. Baxter International Inc has a 52-week low of $43.81 and a 52-week high of $66.18. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. Baxter International’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 earnings per share. analysts anticipate that Baxter International Inc will post 2.43 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 1st will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date is Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is presently 34.41%.
A number of hedge funds have recently modified their holdings of BAX. Baker Ellis Asset Management LLC purchased a new position in Baxter International during the second quarter worth about $109,000. BP PLC raised its stake in Baxter International by 118.8% during the second quarter. BP PLC now owns 151,000 shares of the medical instruments supplier’s stock worth $9,140,000 after purchasing an additional 82,000 shares during the period. Cigna Investments Inc. New raised its stake in Baxter International by 8.7% during the second quarter. Cigna Investments Inc. New now owns 21,494 shares of the medical instruments supplier’s stock worth $1,305,000 after purchasing an additional 1,723 shares during the period. Canada Pension Plan Investment Board raised its stake in Baxter International by 16.1% during the second quarter. Canada Pension Plan Investment Board now owns 1,040,554 shares of the medical instruments supplier’s stock worth $62,995,000 after purchasing an additional 144,400 shares during the period. Finally, Rhumbline Advisers raised its stake in Baxter International by 1.5% during the second quarter. Rhumbline Advisers now owns 837,314 shares of the medical instruments supplier’s stock worth $50,691,000 after purchasing an additional 12,633 shares during the period. 83.59% of the stock is currently owned by institutional investors.
Several analysts have recently issued reports on BAX shares. Royal Bank Of Canada reiterated a “hold” rating and issued a $60.00 target price on shares of Baxter International in a research report on Friday, September 1st. Bank of America restated a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Citigroup initiated coverage on shares of Baxter International in a research report on Thursday, August 17th. They set a “neutral” rating and a $63.00 price target on the stock. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a research report on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “hold” rating and set a $65.00 price target on shares of Baxter International in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Baxter International currently has an average rating of “Buy” and a consensus price target of $67.46.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/09/insider-selling-baxter-international-inc-bax-svp-sells-2176087-50-in-stock.html.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc and related companies with MarketBeat.com's FREE daily email newsletter.